SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma sold 6,944 Ordinary Shares in an open-market transaction at a weighted average price of about $5.51 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following this tax-related sale, he continues to hold 197,456 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on June 25, 2026 at a weighted average price of $5.5049 per share. The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Menu directly holds 240,780 Ordinary Shares, indicating he retained a substantial position in the company.
SOPH affiliate reported proposed and recent sales of Common Stock on Form 144. The filing lists multiple 10b5-1 sales by Jurgi Camblong, with individual transactions such as 43,129 shares on 04/14/2026 and 17,473 shares on 04/15/2026, and additional sales across April–June 2026. The filing lists Morgan Stanley Smith Barney LLC as broker.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported a small open-market sale of 774 Ordinary Shares. The shares were sold at a weighted average price of $5.3795 per share on June 22, 2026, and he held 310,684 shares afterward.
According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on June 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary.
SOPHiA GENETICS SA President Ross Muken reported an open-market sale of 422 Ordinary Shares at a weighted average price of $5.3803 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations tied to the vesting of restricted stock units on June 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Following this small, tax-related transaction, he directly holds 680,489 Ordinary Shares.
SOPH affiliate filed a Form 144 notifying a proposed sale of 774 shares of Common Stock issuable upon Restricted Stock Units dated 06/18/2026. The excerpt also lists prior 10b5-1 dispositions of Common shares on 04/06/2026, 04/07/2026, and 04/08/2026, with per-trade share counts shown.
Ross J Muken reported multiple 10b5-1 dispositions of Common Stock via Form 144, listing specific sale dates, share counts, and proceeds. The filing also lists Restricted Stock Units dated 06/18/2026.
The excerpt shows sale entries including 05/19/2026 (761 shares for $3,501.06), 04/13/2026 (4,442 shares for $21,166.13), and several April 2026 trades. Broker information lists Morgan Stanley Smith Barney LLC Executive Financial Services.
SOPHiA GENETICS SA director Troy Cox received new equity awards tied to his board service. He was granted 19,724 restricted stock units, each representing one ordinary share valued at $5.46, bringing his direct holdings to 328,743 ordinary shares.
He also received options to purchase 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, increasing his option holdings to 252,809. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, contingent on his continued service.
SOPHiA GENETICS SA director Kathy L. Hibbs received new equity awards as part of her compensation. She was granted 19,724 restricted stock units, each representing one ordinary share, at a reference price of $5.46 per share. Following this award, she directly holds 109,492 ordinary shares.
She also received options to buy 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, bringing her total option holdings to 218,569 share options. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to her continued service.
SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.